Heppner D Gray, Schwenk Robert J, Arnot David, Sauerwein Robert W, Luty Adrian J F
Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Trends Parasitol. 2007 Jul;23(7):293-6. doi: 10.1016/j.pt.2007.05.002. Epub 2007 May 18.
To date, the only pre-blood stage vaccine to confer protection against malaria in field trials elicits both antigen-specific antibody and T-cell responses. Recent clinical trials of new heterologous prime-boost malaria vaccine regimens using DNA, fowlpox or MVA, have chiefly elicited T-cell responses that have promisingly reduced hepatic merozoites in challenge trials, but failed to protect in field trials. These encouraging results suggest further augmentation of T-cell responses to pre-blood stage antigens might one day contribute to a highly protective vaccine. We envision that a highly protective pre-erythrocytic vaccine will likely be based upon a heterologous prime-boost regimen that induces both appropriate T-cell responses as well as robust and protracted antibody production.
迄今为止，唯一一种在现场试验中能提供疟疾防护的血前期疫苗可引发抗原特异性抗体和T细胞反应。近期使用DNA、鸡痘或MVA的新型异源初免-加强疟疾疫苗方案的临床试验，主要引发了T细胞反应，这些反应在攻毒试验中有望减少肝内裂殖子，但在现场试验中未能起到保护作用。这些令人鼓舞的结果表明，进一步增强对血前期抗原的T细胞反应，有朝一日可能有助于研发出一种高度保护性的疫苗。我们设想，一种高度保护性的红细胞前期疫苗可能基于一种异源初免-加强方案，该方案既能诱导适当的T细胞反应，又能产生强大且持久的抗体。
